NextGen Sciences" protein biomarker team has been strengthened with the appointment of Drs Ruth VanBogelen as director of Biomarkers and Proteomics and Walid Qoronfleh as vice president of business development.
VanBogelen's leadership, knowledge and vision will help focus the company's biomarker and proteomics services towards the evolving needs of the pharmaceutical industry. Meanwhile, Qoronfleh's extensive commercial experience in the pharmaceutical sector will support the continued growth of our Biomarker Service business..
These appointments are part of the NextGen Group's strategy to focus resources on growing the biomarker service business to meet the needs of its customers.
Launched in November 2007, NextGen Sciences" service portfolio (biomarkerexpress) includes biomarker discovery, assay development and testing. The suite of services includes proprietary methods to enable biopharma clients, researchers and clinicians to select the best biomarkers for each Research and Development program, and for use in predictive medicine. The Company is currently running a number of biomarker projects in therapeutic areas including oncology and Alzheimer's disease, which are nearing delivery.
NextGen ceo Dr Mike Pisano, said: "Ruth's leadership, knowledge and vision will help us focus our biomarker and proteomics services towards the evolving needs of the pharmaceutical industry. Walid's extensive commercial experience in the pharmaceutical sector will support the continued growth of our Biomarker Service business."
